WallStSmart

Nanobiotix (NBTX)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Nanobiotix generates 4293% more annual revenue ($32.59M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -73.5%. RVMD earns a higher WallStSmart Score of 24/100 (F).

NBTX

Avoid

22

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.5
Piotroski: 4/9Altman Z: -0.63

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NBTX2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
186.8%10/10

Revenue surging 186.8% year-over-year

Debt/EquityHealth
-1.1310/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

NBTX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.93B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-198.7%2/10

ROE of -198.7% — below average capital efficiency

Free Cash FlowQuality
$-16.41M2/10

Negative free cash flow — burning cash

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NBTX

The strongest argument for NBTX centers on Revenue Growth, Debt/Equity. Revenue growth of 186.8% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : NBTX

The primary concerns for NBTX are EPS Growth, Market Cap, Return on Equity.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

NBTX profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

NBTX is growing revenue faster at 186.8% — sustainability is the question.

NBTX generates stronger free cash flow (-16M), providing more financial flexibility.

Bottom Line

RVMD scores higher overall (24/100 vs 22/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Nanobiotix

HEALTHCARE · BIOTECHNOLOGY · USA

Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?